[Remdesivir (COVID-19, requirement for additional oxygen supply, = 4 weeks - < 12 years of age) - Benefit assessment according to § 35a Social Code Book V]

Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018004341
Original Title: Remdesivir (COVID-19, mit zusaetzlicher Sauerstoffzufuhr, ≥ 4 Wochen bis < 12 Jahre)
Project Status: Completed
Year Published: 2023
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • COVID-19
  • COVID-19 Drug Treatment
  • Antiviral Agents
  • Child
  • Child, Preschool
  • Infant
  • SARS-CoV-2
  • Coronavirus Infections
  • Remdesivir
  • COVID-19
  • Child - Preschool
  • Infant
  • Child
  • Benefit Assessment
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.